Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma - Takeaways - MDSpire

Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma

  • By

  • Luisina María Solernó

  • Candela Llavona

  • Zahira Yasmine Saud

  • Mariana Carolina Onassis

  • María Florencia Gottardo

  • Martín Manuel Ledesma

  • Daniel Fernando Alonso

  • Juan Garona

  • July 1, 2026

  • 0 min

Share

  • 1

    Osteosarcoma (OSA) is the most common primary malignant bone tumor, characterized by high mortality and extensive vascularization.

  • 2

    Desmopressin (dDAVP) has shown antitumor and angiostatic properties in other malignancies, but its role in OSA is not fully characterized.

  • 3

    The study evaluated the combined efficacy of dDAVP and Bevacizumab (BEVA) in enhancing antiangiogenic treatment for OSA.

  • 4

    dDAVP significantly reduced pulmonary metastasis and vascularization in OSA models and enhanced the antivascular activity of BEVA.

  • 5

    Combined treatment with dDAVP and BEVA inhibited OSA xenograft progression without overt toxicity, suggesting a potential adjuvant therapy.

Original Source(s)

Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma

  • by Luisina María Solernó, Candela Llavona, Zahira Yasmine Saud, Mariana Carolina Onassis, María Florencia Gottardo, Martín Manuel Ledesma, Daniel Fernando Alonso, Juan Garona

  • July 1, 2026

Related Content

Evaluating the accuracy and communication quality of large language models in Ewing sarcoma: a comparative analysis of ChatGPT, Claude, Gemini, DeepSeek, and Grok

Artificial intelligence for triple-negative breast cancer from imaging to multi-omics

Multimodal imaging features of primary breast epithelial–myoepithelial carcinoma: a case report and literature review